Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia

Valentina Svicher, Claudia Alteri, Caterina Gori, Romina Salpini, Fabbio Marcuccilli, Ada Bertoli, Roberta Longo, Martina Bernassola, Valentina Gallinaro, Sara Romano, Michela Visca, Antonella Ursitti, Marcello Feasi, Valeria Micheli, Mario Angelico, Giovanni Cassola, Giustino Parruti, Guido Gubertini, Giuseppe Maria De Sanctis, Francesca Ceccherini-SilbersteinGiuseppina Cappiello, Alberto Spanò, Carlo Federico Perno

Research output: Contribution to journalArticlepeer-review


Objective: To investigate lamivudine (LAM)-resistance profiles of hepatitis B virus (HBV) at the early stages of virological breakthrough (serum HBV-DNA 12-345. IU/ml) or when HBV-DNA is undetectable. Methods: Sixty-four HBV-mono-infected patients were enrolled: 25 had virological breakthrough with serum HBV-DNA ranging from 12 to 345. IU/ml during first-line LAM-monotherapy; 24 were on LAM-monotherapy, and 15 were on LAM. +. adefovir dipivoxil (ADV) with undetectable serum HBV-DNA (

Original languageEnglish
Pages (from-to)902-907
Number of pages6
JournalDigestive and Liver Disease
Issue number12
Publication statusPublished - Dec 2010


  • Drug resistance
  • HBV
  • Low viral replication

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology


Dive into the research topics of 'Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia'. Together they form a unique fingerprint.

Cite this